Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
–PH-762 is Phio's lead product candidate
—PH-762 是 Phio 的主要候選產品
-Screening on the next cohort is on-going
-正在對下一批人進行篩查
MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced progress on its Phase 1b clinical study for their lead compound PH-762. Dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going.
馬薩諸塞州馬爾伯勒，2024年5月15日（環球新聞專線）——Phio製藥公司（納斯達克股票代碼：PHIO）是一家臨床階段的生物技術公司，其專有的INTASYL siRNA基因沉默技術旨在使免疫細胞更有效地殺死腫瘤細胞，今天宣佈其主要化合物 PH-762 的1b期臨床研究取得進展。第一組患者的給藥已經完成，下一個劑量隊列的篩查正在進行中。
Phio's Phase 1b study (NCT 06014086) is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This study will assess the tumor response, and determine the recommended dose for further study of PH-762.
Phio 的 1b 期研究（NCT 06014086）是一項多中心、劑量遞增的臨床試驗，旨在評估在皮膚鱗狀細胞癌、黑色素瘤或默克爾細胞癌中使用腫瘤 PH-762 的新輔助應用的安全性和耐受性。該研究將評估腫瘤反應，並確定進一步研究 PH-762 的推薦劑量。
"This is exciting news for Phio and our lead compound PH-762 with the dosing of the 1st cohort completed, we look forward to advancing the study to bring an innovative treatment option to patients with skin carcinomas," said Robert Bitterman, CEO of Phio Pharmaceuticals.
“對於 Phio 和我們的主要化合物 PH-762 來說，這是個令人振奮的消息，其劑量爲 1st 隊列已經完成，我們期待推進這項研究，爲皮膚癌患者帶來創新的治療選擇。” Phio Pharmicals首席執行官羅伯特·比特曼說。
About Phio Pharmaceuticals Corp.
Phio 製藥公司簡介
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Phio製藥公司（納斯達克股票代碼：PHIO）是一家臨床階段的生物技術公司，其專有的INTASYL siRNA基因沉默技術旨在使免疫細胞更有效地殺死腫瘤細胞。INTASYL 是唯一專注於免疫腫瘤學療法的自交式 RNAi 技術。INTASYL 藥物可精確靶向降低人體抗癌能力的特定蛋白質，無需專門的配方或藥物輸送系統。
欲了解更多信息，請訪問公司的網站， www.phiopharma.com。
Forward Looking Statements
前瞻性陳述
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward-looking statements include statements regarding the potential of PH-762 to treat skin carcinomas. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述。前瞻性陳述可以通過諸如 “打算”、“相信”、“預期”、“計劃”、“預期”、“建議”、“可能”、“將”、“潛在”、“設計用於”、“將”、“持續”、“估計”、“預測”、“目標”、“預測”、“可能” 等詞語來識別，儘管不是所有前瞻性陳述包含這些單詞。這些陳述僅基於我們當前的信念、預期和假設，並受固有的不確定性、風險和環境變化的影響，這些因素難以預測，其中許多是我們無法控制的。前瞻性陳述的示例包括關於 PH-762 治療皮膚癌潛力的陳述。由於許多重要因素，我們的實際業績可能與前瞻性陳述中顯示的結果存在重大差異，包括但不限於通貨膨脹壓力、利率上升、經濟衰退擔憂、候選產品的開發、臨床前和臨床活動的結果、我們執行業務戰略的能力、我們與合作伙伴開發候選產品的能力以及任何此類合作的成功，時間表和持續時間包括推動我們的候選產品進入臨床開發階段、監管機構申請和批准的時機或可能性、我們在獲得批准後將候選產品商業化的努力是否成功、我們爲臨床活動以及獲得批准後用於商業用途的候選產品的能力、我們能夠確立和維持的涵蓋技術平台的知識產權的保護範圍、我們獲得未來融資、市場和其他條件以及我們的年度報告中確定的條件的能力10-K表格及隨後的10-Q表季度報告，標題爲 “風險因素”，以及公司定期向美國證券交易委員會提交的其他文件。我們敦促讀者審查這些風險因素，不要依賴任何前瞻性陳述行事，因爲實際結果可能與我們的前瞻性陳述所設想的結果有所不同。除非法律要求，否則Phio不承諾更新前瞻性陳述以反映本新聞稿發佈之日後發生的觀點、事件或情況的變化。
Contact:
Phio Pharmaceuticals Corp.
ir@phiopharma.com
聯繫人：
菲奧製藥公司
ir@phiopharma.com
PR Contact
Michael Adams
Bridge View Media
adams@bridgeviewmedia.com
公關聯繫人
邁克·亞當斯
橋景媒體
adams@bridgeviewmedia.com
譯文內容由第三人軟體翻譯。